STTK · Insider Trading
Shattuck Labs, Inc. Common Stock
Every open-market purchase and sale reported by STTK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-07 | Abhinav A. Shukla | Chief Technical Officer | MIXED | +12,153 | +$41.98K |
| 2026-07-02 | Arundathy N. Pandite | Chief Medical Officer | Sell | −30,000 | −$210.30K |
| 2026-07-02 | Abhinav A. Shukla | Chief Technical Officer | MIXED | — | −$82.36K |
| 2026-06-15 | Mona Ashiya | Director | Buy | — | — |
| 2026-06-15 | OrbiMed Genesis GP LLC | Director | Buy | — | — |
| 2026-06-11 | Clay B Siegall | Director | Buy | +62,500 | +$250.00K |
| 2026-06-09 | Mona Ashiya | Director | C | — | — |
| 2026-06-09 | OrbiMed Genesis GP LLC | Director | C | — | — |
| 2026-06-02 | Helen M Boudreau | Director | A | +81,000 deriv. | — |
| 2026-06-02 | Neil W Gibson | Director | A | +81,000 deriv. | — |
| 2026-06-02 | Daniel G. Baker | Director | A | +81,000 deriv. | — |
| 2026-06-02 | Mona Ashiya | Director | A | +81,000 deriv. | — |
| 2026-06-02 | George Golumbeski | Director | A | +81,000 deriv. | — |
| 2026-06-02 | Clay B Siegall | Director | A | +81,000 deriv. | — |
| 2026-05-27 | Clay B Siegall | Director | A | +128,054 | +$138.89K |
| 2026-05-21 | Abhinav A. Shukla | Chief Technical Officer | A | +5,122 | +$5.56K |
| 2026-05-18 | Stephen Stout | See Remarks | A | +12,805 | +$13.89K |
| 2026-05-14 | Arundathy N. Pandite | Chief Medical Officer | Sell | −30,000 | −$198.30K |
| 2026-05-14 | Abhinav A. Shukla | Chief Technical Officer | MIXED | — | −$6.99K |
| 2026-05-14 | Andrew R Neill | Chief Financial Officer | A | +64,027 | +$69.44K |
| 2026-05-13 | Taylor Schreiber | Chief Executive Officer | A | +25,610 | +$27.78K |
| 2026-05-12 | Stephen Stout | See Remarks | F | −968 | −$6.63K |
| 2026-01-27 | Stephen Stout | See Remarks | F | −593 | −$2.46K |
| 2026-01-27 | Casi DeYoung | Chief Business Officer | F | −2,286 | −$9.49K |
| 2026-01-27 | Andrew R Neill | Chief Financial Officer | F | −2,589 | −$10.74K |
| 2026-01-27 | Arundathy N. Pandite | Chief Medical Officer | F | −3,195 | −$13.26K |
| 2026-01-13 | Abhinav A. Shukla | Chief Technical Officer | A | +315,500 deriv. | — |
| 2026-01-13 | Stephen Stout | See Remarks | F | −4,153 | −$19.73K |
| 2026-01-13 | Casi DeYoung | Chief Business Officer | F | −5,699 | −$27.07K |
| 2026-01-13 | Andrew R Neill | Chief Financial Officer | F | −6,660 | −$31.64K |
| 2026-01-13 | Taylor Schreiber | Chief Executive Officer | A | +1,548,300 deriv. | — |
| 2026-01-13 | Arundathy N. Pandite | Chief Medical Officer | F | −6,851 | −$32.54K |
| 2025-09-02 | Mona Ashiya | Director | A | +66,300 deriv. | — |
| 2025-09-02 | Daniel G. Baker | Director | A | +66,300 deriv. | — |
| 2025-09-02 | OrbiMed Capital GP IX LLC | Director | Buy | +18,918,381 | +$16.42M |
| 2025-09-02 | Mona Ashiya | Director | Buy | +6,306,127 | +$5.47M |
| 2025-08-27 | Stephen Stout | See Remarks | A | +12,805 | +$11.11K |
| 2025-08-27 | Taylor Schreiber | Chief Executive Officer | A | +25,610 | +$22.22K |
| 2025-08-27 | Abhinav A. Shukla | Chief Technical Officer | A | +5,122 | +$4.44K |
| 2025-08-27 | Andrew R Neill | Chief Financial Officer | A | +64,027 | +$55.56K |
| 2025-08-27 | Clay B Siegall | Director | A | +128,054 | +$111.11K |
| 2025-08-26 | Jeremy Green | Director | A | +16,390,920 deriv. | — |
| 2025-07-16 | Amy Kate Sasser | Director | A | +33,150 deriv. | — |
| 2025-07-16 | Clay B Siegall | Director | A | +33,150 deriv. | — |
| 2025-07-16 | Jeremy Green | Director | A | +66,300 deriv. | — |
| 2025-07-16 | Tyler Brous | Director | A | +33,150 deriv. | — |
| 2025-07-16 | Michael Stewart Lee | Director | A | +33,150 deriv. | — |
| 2025-07-16 | Neil W Gibson | Director | A | +33,150 deriv. | — |
| 2025-07-16 | George Golumbeski | Director | A | +33,150 deriv. | — |
| 2025-07-16 | Carrie Brownstein | Director | A | +33,150 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jeremy Green | Director | 5,615,489 | $30.80M |
| Redmile Group, LLC | Director | 5,539,724 | $30.39M |
| Taylor Schreiber | Chief Executive Officer | 2,732,972 | $14.99M |
| Mona Ashiya | Director | 1,051,021 | $5.76M |
| OrbiMed Genesis GP LLC | Director | 1,051,021 | $5.76M |
| OrbiMed Capital GP IX LLC | Director | 1,051,021 | $5.76M |
| Clay B Siegall | Director | 318,608 | $1.75M |
| Andrew R Neill | Chief Financial Officer | 292,251 | $1.60M |
| Tyler Brous | Director | 235,088 | $1.29M |
| Arundathy N. Pandite | Chief Medical Officer | 136,219 | $747.16K |
| Abhinav A. Shukla | Chief Technical Officer | 98,533 | $540.45K |
| Stephen Stout | See Remarks | 93,366 | $512.11K |
| Casi DeYoung | Chief Business Officer | 73,480 | $403.04K |
| George Golumbeski | Director | 54,613 | $299.55K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the STTK quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.